Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Goldman, Jonathan W.
Horinouchi, Hidehito
Cho, Byoung Chul
Tomasini, Pascale
Dunbar, Martin
Hoffman, David
Parikh, Apurvasena
Blot, Vincent
Camidge, D. Ross
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] Natl Canc Ctr, Tokyo, Japan
[3] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[4] Aix Marseille Univ, Hop Nord, APHM, INSERM,CNRS,CRCM,Multidisciplinary Oncol & Therap, Marseille, France
[5] AbbVie Inc, N Chicago, IL USA
[6] AbbVie Inc, South San Francisco, CA USA
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9013
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
    Horinouchi, H.
    Goldman, J. W.
    Cho, B. C.
    Tomasini, P.
    Dunbar, M.
    Hoffman, D.
    Parikh, A.
    Blot, V.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2022, 33 : S1592 - S1592
  • [2] EGFR M plus Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met plus Non-Small Cell Lung Cancer
    Camidge, D. R.
    Barlesi, F.
    Goldman, J.
    Morgensztern, D.
    Heist, R.
    Vokes, E.
    Spira, A.
    Angevin, E.
    Su, W.
    Hong, D.
    Strickler, J.
    Motwani, M.
    Sun, Z.
    Parikh, A.
    Komarnitsky, P.
    Wu, J.
    Kelly, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S305 - S306
  • [3] Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates
    Horinouchi, H.
    Cho, B. C.
    Camidge, D. R.
    Goto, K.
    Tomasini, P.
    Li, Y.
    Vasilopoulos, A.
    Brunsdon, P.
    Hoffman, D.
    Shi, W.
    Blot, V.
    Goldman, J. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1670 - S1670
  • [4] c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.
    Heist, Rebecca Suk
    Motwani, Monica
    Barlesi, Fabrice
    Goldman, Jonathan Wade
    Kelly, Karen
    Sun, Yan
    Wu, Jun
    Bach, Bruce Allen
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET plus Non-Small Cell Lung Cancer: Trial in Progress
    Ocampo, C.
    Wu, J.
    Dey, J.
    Sun, Z.
    Motwani, M.
    Reddy, A.
    Parikh, A.
    Hay, J.
    Komarnitsky, P.
    Bach, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S646
  • [6] Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met plus non-small cell lung cancer by EGFR mutation status.
    Camidge, D. Ross
    Barlesi, Fabrice
    Goldman, Jonathan Wade
    Morgensztern, Daniel
    Heist, Rebecca Suk
    Vokes, Everett E.
    Spira, Alexander I.
    Angevin, Eric
    Su, Wu-Chou
    Hong, David S.
    Strickler, John H.
    Motwani, Monica
    Sun, Zhaowen
    Parikh, Apurvasena
    Noon, Elysa
    Wu, Jun
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC).
    Camidge, D. Ross
    Bar, Jair
    Horinouchi, Hidehito
    Goldman, Jonathan W.
    Moiseenko, Fedor Vladimirovich
    Filippova, Elena
    Cicin, Irfan
    Bradbury, Penelope Ann
    Daaboul, Nathalie
    Tomasini, Pascale
    Ciuleanu, Tudor-Eliade
    Planchard, David
    Moskovitz, Mor
    Girard, Nicolas
    Jin, Janet Yikai
    Dunbar, Martin
    Bolotin, Ellen
    Looman, Jim
    Ratajczak, Christine
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer
    Camidge, D. R.
    Moiseenko, F.
    Cicin, I.
    Horinouchi, H.
    Filippova, E.
    Bar, J.
    Lu, S.
    Tomasini, P.
    Ocampo, C.
    Sullivan, D.
    Maag, D.
    Goldman, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S875 - S875
  • [9] Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer.
    Camidge, D. Ross
    Moiseenko, Fedor
    Cicin, Irfan
    Horinouchi, Hidehito
    Filippova, Elena
    Bar, Jair
    Lu, Shun
    Tomasini, Pascale
    Ocampo, Christopher
    Sullivan, Danielle
    Maag, David
    Goldman, Jonathan W.
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Patient-reported outcomes (PROs) from a phase 2 trial of telisotuzumab vedotin (Teliso-V) in c-Met-overexpressing, EGFR wild type, non-squamous non-small cell lung cancer (c-Met OE, EGFR WT, NSq NSCLC)
    Lu, S.
    Bar, J.
    Girard, N.
    Xu, Q.
    Sen, R.
    Ratajczak, C.
    Ng, S.
    Xia, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2023, 34
12345